S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
VYGR · Voyager Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Voyager Therapeutics Inc (VYGR)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$2.02
-0.17
(-7.78%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$2.02
$2.00
$2.15
52-WEEK RANGE
$2.02
$1.89
$5.48
What's happening
- VYGR is down 7.78% today, trading at $2.02. — Live quote
- Volume today (68,745) is well below its 3-month average of 638,740. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.40 actual vs. $-0.49 estimated (+19.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
VYGR
-44.27%
vs S&P 500
-57.05%
1-YEAR RETURN
VYGR
-56.80%
vs S&P 500
-71.37%
6-MONTH RETURN
VYGR
-44.70%
3-MONTH RETURN
VYGR
-30.25%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.40
Est. $-0.49
BEAT +19.0%
2026-04-26 (Q1 2026)
$-0.47
Est. $-0.56
BEAT +16.4%
2026-01-26 (Q4 2025)
$-0.46
Est. $-0.52
BEAT +11.7%
2025-10-26 (Q3 2025)
$-0.47
Est. $-0.53
BEAT +11.5%
Valuation Measures & Ratios
Enterprise Value4$90.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)3.65
Price / Book71.37
EV4 / Revenue2.62
EV4 / EBITDA6.48
Profit Margin-312.63%
Operating Margin-340.08%
Return on Equity (ROE8)-57.92%
Return on Assets (ROA9)-45.00%
Avg Volume (3M)638,740
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $213.8M | $229.7M | $277.7M | $181.8M | $198.4M |
| P/E | -1.88 | -1.91 | -2.74 | -2.18 | -3.22 |
| Price/Sales | 8.79 | 8.31 | 5.59 | 2.76 | 2.47 |
| Price/Book | 1.39 | 1.32 | 1.26 | 0.75 | 0.73 |
| EV/Revenue | 7.32 | 6.75 | 4.68 | 2.09 | 1.54 |
| ROE | -73.64% | -69.23% | -46.10% | -34.27% | -22.57% |
| ROA | -57.49% | -54.82% | -35.15% | -25.95% | -17.42% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,973,207
Change from Prior Settlement+8.68%
% of Float—
Days to Cover (Short Ratio)6.43
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-21; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -39.1% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -312.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -56.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on VYGR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2M | $2.6M | $13.4M | $5.2M | $6.5M | $24.6M | $29.6M | $19.5M |
| Operating income | -$26.4M | -$30.3M | -$30.6M | -$36.6M | -$34.7M | -$13.8M | -$15.0M | -$16.2M |
| Net income | -$24.5M | -$27.9M | -$27.9M | -$33.4M | -$31.0M | -$9.0M | -$10.1M | -$11.3M |
| EPS (diluted) | $-0.40 | $-0.47 | $-0.47 | $-0.57 | $-0.53 | $-0.16 | $-0.18 | $-0.20 |
| EPS (basic) | $-0.40 | $-0.47 | $-0.47 | $-0.57 | $-0.53 | $-0.16 | $-0.18 | $-0.20 |
| Operating margin | -$834 | -$1.2K | -$229 | -$704 | -$536 | -$56 | -$51 | -$83 |
| Net margin | -$773 | -$1.1K | -$209 | -$642 | -$479 | -$37 | -$34 | -$58 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $197.8M | $219.3M | $252.3M | $288.3M | $322.1M | $353.2M | $393.1M | $426.0M |
| Total liabilities | $43.4M | $45.7M | $56.2M | $68.5M | $78.2M | $80.5M | $93.3M | $95.7M |
| Stockholders' equity | $154.4M | $173.7M | $196.1M | $219.8M | $243.9M | $272.7M | $299.8M | $330.3M |
| Total current assets | $125.2M | $147.0M | $202.7M | $219.6M | $227.9M | $245.2M | $276.8M | $373.4M |
| Total current liabilities | $16.7M | $17.5M | $26.5M | $35.5M | $42.0M | $40.2M | $49.8M | $44.2M |
| Cash & equivalents | $35.8M | $43.3M | $65.3M | $45.1M | $43.9M | $74.8M | $71.4M | $112.5M |
| Marketable securities (current) | $80.6M | $98.2M | $131.1M | $163.8M | $171.7M | $161.3M | $195.3M | $232.8M |
| Accounts receivable | $2.9M | $1.5M | $1.8M | $3.2M | $1.7M | $1.6M | $1.5M | $16.0M |
| Other current assets | — | — | $2.3M | — | — | — | $2.9M | — |
| Marketable securities (non-current) | $32.5M | $30.2M | $5.2M | $20.1M | $46.4M | $59.1M | $65.7M | — |
| Property, plant & equipment | $11.2M | $12.2M | $13.1M | $13.3M | $13.9M | $13.9M | $14.3M | $15.2M |
| Other non-current assets | $214.0K | — | — | — | — | — | — | — |
| Accounts payable | $1.6M | $2.7M | $5.0M | $2.1M | $1.8M | $2.6M | $4.0M | $3.2M |
| Accrued liabilities | $8.0M | $7.0M | $12.1M | $15.0M | $12.0M | $9.1M | $14.2M | $11.4M |
| Deferred revenue (current) | $244.0K | $395.0K | $1.6M | $10.6M | $20.5M | $21.1M | $24.4M | $22.6M |
| Other current liabilities | — | — | — | — | — | — | $7.2M | $7.0M |
| Other non-current liabilities | — | — | — | — | — | — | $37.5M | $39.4M |
| Common stock & paid-in capital | $61.0K | $60.0K | $59.0K | $56.0K | $56.0K | $55.0K | $55.0K | $55.0K |
| Retained earnings | -$498.3M | -$473.8M | -$445.9M | -$418.5M | -$390.6M | -$357.2M | -$326.2M | -$291.7M |
| Accumulated other comprehensive income (loss) | -$421.0K | -$263.0K | $32.0K | $7.0K | -$221.0K | -$199.0K | -$407.0K | -$33.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.8M | -$33.4M | -$30.3M | -$31.0M | -$33.3M | -$37.9M | -$14.5M | -$28.0M |
| Investing cash flow | $15.4M | $8.1M | $47.4M | $34.9M | $1.9M | $41.2M | -$27.2M | $64.4M |
| Financing cash flow | $2.9M | $3.3M | $136.0K | $85.0K | $513.0K | $82.0K | $574.0K | $14.0K |
| Free cash flow | -$25.8M | -$33.4M | -$30.9M | -$31.3M | -$34.4M | -$38.6M | -$14.7M | -$28.2M |
| Capital expenditures | $0 | $14.0K | $626.0K | $207.0K | $1.1M | $658.0K | $155.0K | $258.0K |
| Share-based compensation | $2.4M | $2.5M | $3.5M | $3.5M | $4.1M | $3.7M | $3.7M | $3.4M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $1.4M | -$267.0K | -$1.4M | $1.5M | $51.0K | $119.0K | -$14.4M | $14.3M |
| Change in accounts payable | -$1.1M | -$2.3M | $2.9M | $312.0K | -$830.0K | -$1.4M | $836.0K | $555.0K |
| Purchases of investments | $27.4M | $43.4M | $12.5M | $6.6M | $37.9M | $76.9M | $131.0M | $40.8M |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $40.4M | $80.0M | $250.0M | $40.9M | $37.4M |
| Operating income | -$131.8M | -$83.3M | $122.0M | -$50.8M | -$73.6M |
| Net income | -$119.7M | -$65.0M | $132.3M | -$46.4M | -$71.2M |
| EPS (diluted) | $-2.04 | $-1.13 | $2.97 | $-1.21 | $-1.89 |
| EPS (basic) | $-2.04 | $-1.13 | $3.08 | $-1.21 | $-1.89 |
| Operating margin | -$327 | -$104 | $49 | -$124 | -$197 |
| Net margin | -$297 | -$81 | $53 | -$113 | -$190 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $252.3M | $393.1M | $351.3M | $159.4M | $193.9M |
| Total liabilities | $56.2M | $93.3M | $115.0M | $100.3M | $98.8M |
| Stockholders' equity | $196.1M | $299.8M | $236.3M | $59.0M | $95.1M |
| Total current assets | $202.7M | $276.8M | $319.7M | $124.5M | $136.7M |
| Total current liabilities | $26.5M | $49.8M | $64.5M | $72.6M | $51.0M |
| Cash & equivalents | $65.3M | $71.4M | $68.8M | $99.0M | $117.4M |
| Marketable securities (current) | $131.1M | $195.3M | $162.1M | $19.9M | $15.1M |
| Accounts receivable | $1.8M | $1.5M | $80.2M | — | — |
| Other current assets | $2.3M | $2.9M | $2.6M | $4.2M | $1.7M |
| Marketable securities (non-current) | $5.2M | $65.7M | — | — | — |
| Property, plant & equipment | $13.1M | $14.3M | $16.5M | $17.9M | $21.9M |
| Accounts payable | $5.0M | $4.0M | $1.6M | $2.6M | $574.0K |
| Accrued liabilities | $12.1M | $14.2M | $16.8M | $7.8M | $10.9M |
| Deferred revenue (current) | $1.6M | $24.4M | $42.9M | $59.4M | $33.9M |
| Other current liabilities | — | $7.2M | $3.2M | $2.8M | $5.6M |
| Other non-current liabilities | — | $37.5M | $18.1M | $21.3M | $39.6M |
| Common stock & paid-in capital | $59.0K | $55.0K | $44.0K | $38.0K | $38.0K |
| Retained earnings | -$445.9M | -$326.2M | -$261.2M | -$393.5M | -$347.1M |
| Accumulated other comprehensive income (loss) | $32.0K | -$407.0K | -$48.0K | -$219.0K | -$138.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$132.5M | -$15.3M | $77.9M | -$12.5M | -$53.5M |
| Investing cash flow | $125.4M | -$94.9M | -$141.6M | -$7.3M | $65.9M |
| Financing cash flow | $816.0K | $114.0M | $33.6M | $1.1M | $612.0K |
| Free cash flow | -$135.1M | -$18.8M | $74.7M | -$15.0M | -$55.1M |
| Capital expenditures | $2.6M | $3.5M | $3.3M | $2.5M | $1.6M |
| Share-based compensation | $14.8M | $14.8M | $11.2M | $9.3M | $11.3M |
| Deferred income taxes | — | — | — | — | — |
| Change in accounts receivable | $257.0K | -$78.6M | $80.2M | — | — |
| Change in accounts payable | $1.0M | $2.4M | -$962.0K | $2.0M | -$60.0K |
| Purchases of investments | $133.9M | $465.7M | $224.0M | $54.8M | $15.1M |
| Sales/maturities of investments | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding VYGR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-06 to 2026-04-02
Recent transactions
- Most recent: Sandrock Alfred (President and CEO) — Open market sale of 11,511 shares on 2026-04-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Sandrock Alfred | President and CEO | Open market sale | 2026-04-02 | 11,511 |
| Shiferman Gregory L. | SVP and General Counsel | Grant / award | 2026-04-01 | 50,000 |
| Swartz Robin | COO & CBO | Open market sale | 2026-02-24 | 6,458 |
| Jorgensen Nathan D. | Chief Financial Officer | Open market sale | 2026-02-24 | 4,668 |
| Carter Todd Alfred | Chief Scientific Officer | Open market sale | 2026-02-24 | 4,174 |
| Ferguson Toby | Chief Medical Officer | Grant / award | 2026-02-06 | 45,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-04-02 | Sandrock Alfred | President and CEO | Open market sale | 11,511 | $3.87 |
| 2026-04-01 | Shiferman Gregory L. | SVP and General Counsel | Grant / award | 50,000 | $0.00 |
| 2026-02-24 | Swartz Robin | COO & CBO | Open market sale | 6,458 | $3.77 |
| 2026-02-24 | Sandrock Alfred | President and CEO | Open market sale | 14,197 | $3.79 |
| 2026-02-24 | Jorgensen Nathan D. | Chief Financial Officer | Open market sale | 4,668 | $3.77 |
| 2026-02-24 | Carter Todd Alfred | Chief Scientific Officer | Open market sale | 4,174 | $3.76 |
| 2026-02-18 | Swartz Robin | COO & CBO | Open market sale | 3,882 | $3.44 |
| 2026-02-18 | Carter Todd Alfred | Chief Scientific Officer | Open market sale | 3,301 | $3.44 |
| 2026-02-18 | Sandrock Alfred | President and CEO | Open market sale | 11,732 | $3.41 |
| 2026-02-10 | Swartz Robin | COO & CBO | Open market sale | 4,569 | $3.85 |
| 2026-02-10 | Sandrock Alfred | President and CEO | Open market sale | 12,192 | $3.78 |
| 2026-02-10 | Carter Todd Alfred | Chief Scientific Officer | Open market sale | 3,525 | $3.85 |
| 2026-02-06 | Ferguson Toby | Chief Medical Officer | Grant / award | 45,000 | $0.00 |
| 2026-02-06 | Carter Todd Alfred | Chief Scientific Officer | Grant / award | 33,000 | $0.00 |
| 2026-02-06 | Swartz Robin | COO & CBO | Grant / award | 45,000 | $0.00 |
| 2026-02-06 | Sandrock Alfred | President and CEO | Grant / award | 86,250 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:06 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-21 | 8-K | 2026-10-20 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-13 | 8-K | 2026-07-13 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
Recent news
Headlines about VYGR (Voyager Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Form 8K Voyager Therapeutics Inc For: 21 October By Investing.com
Investing.com India · 2026-10-21 -
Robin Swartz Appointed President of Voyager Therapeutics with CEO Succession Planned for 2027
Kalkine Media · 2026-10-21 -
Voyager Therapeutics names Robin Swartz as successor to CEO Alfred Sandrock
Seeking Alpha · 2026-10-21 -
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
Yahoo · 2026-10-21 -
Voyager Therapeutics Appoints Robin Swartz As President, Effective October 20, And Is Expected To Become CEO In Q1 2027
Benzinga · 2026-10-21 -
HC Wainwright keeps USD 25 target for Voyager Therapeutics stock
AD HOC NEWS · 2026-10-20 -
Wells Fargo kept USD 10 target for Voyager Therapeutics stock
AD HOC NEWS · 2026-10-18 -
HNST,EXFY,VYGR,GLSI,UNFI,AURA,JOBY,NXH | Stock Prices | Quote Comparison - Yahoo Finance
Yahoo! Finance Canada · 2026-10-17
No headlines in this category right now — try “All”.